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Abstract 
The 11-year survival of a woman with recurrent progressive advanced epithelial ovarian 
cancer emphasizes the potential for the disease process to be quite ‘chronic’ in nature. 
 
Introduction 
A previously published commentary has noted that for many women with recurrent or 
persistent advanced ovarian or primary peritoneal cancer, it is not unreasonable to 
consider the disease to be a very serious, but chronic disease process [1]. The implications 
of this statement include the fact that while cure is unfortunately not an objectively valid 
goal of therapy in this setting, prolonged survival is possible [2, 3], and that treatment 
strategies should essentially be designed to focus equally on the quality of life as well as 
the length of survival. The 11-year survival of a patient under the care of one of the 
authors of this report (V.M.) who has received multiple treatments for recurrent and 
progressive disease emphasizes the meaning and complexity of this far from theoretical 
management paradigm. 
Case Report 
The patient was diagnosed with stage IIIC papillary serous adenocarcinoma of the peritoneum in 
September 1997. Following primary cytoreductive surgery, the patient developed a vesicovaginal fistula  
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which was managed conservatively. Her primary chemotherapy consisted of carboplatin and paclitaxel. 
Due to the extent of the initial disease process, the patient received several sequential ‘maintenance 
approaches’, including paclitaxel, altretamine, and tamoxifen (each delivered as single agent). A 
secondary cytoreductive surgical procedure was performed due to the presence of documented 
recurrent macroscopic disease. 
Since the documentation of recurrence the patient has received the following sequential 
antineoplastic regimens over a multi-year period: (a) carboplatin plus gemcitabine (with carboplatin, 
and subsequently gemcitabine, being discontinued due to hypersensitivity reactions); (b) cisplatin plus 
paclitaxel; (c) single agent altretamine; (d) cisplatin plus docetaxel; (e) single agent anastrozole; 
(f) cisplatin plus paclitaxel; (g) single agent paclitaxel; (h) single agent altretamine; (i) raloxifene (most 
recent treatment, initiated in May 2008). In addition to the antineoplastic drug therapy, the patient has 
undergone two additional major surgical procedures in 2004 and 2006 to resect progressive 
macroscopic cancer. 
At the time of this report (September 2008), the patient remains without cancer-related symptoms, 
with no radiographic evidence of the malignancy (normal whole-body PET scan), and with a normal 
serum CA-125 antigen level, 11 years after the initial diagnosis of advanced ovarian cancer and 
following treatment of multiple episodes of progressive disease. 
Discussion 
An increasing number of therapeutic options are available to women with epithelial 
ovarian cancer who experience recurrence or persistence of their disease following the 
delivery of the initial treatment program [4, 5]. 
Surgery can play a critically important role in this setting, both to potentially improve 
the opportunity for a more prolonged response to subsequently delivered cytotoxic 
chemotherapy following an extended treatment-free interval [6], and to palliate 
distressing symptoms associated with progression of platinum-resistant cancer. Judicious 
use of radiation, most frequently in the presence of resistant disease symptomatically 
localized to the pelvis, can be particularly effective in the short-term palliation of pain. 
Chemotherapy delivered in the setting of recurrent or platinum-resistant cancer has 
been documented to extend survival [7–9], may improve cancer-related symptoms, and 
can meaningfully delay further disease progression. Unfortunately, the selection of 
specific therapies considered during the course of an extended illness must be quite 
empiric, based principally on physician judgment, knowledge of specific toxicities 
experienced by the individual patient, limited data from clinical trials (mostly phase 2 
studies), and patient choice. 
It is often difficult to know if observed prolonged survival, such as in the case 
presented here, is the result of the unique natural history of disease in a particular 
individual, or represents the favorable impact of the multiple therapies employed, or 
(most likely) a variable combination of these two factors [10]. Of note, the recently 
reported results of a randomized phase 3 trial have impressively demonstrated that even 
when delivered in the ‘third-line’ setting to patients with platinum-resistant ovarian 
cancer, biologically active anticancer therapy can significantly improve overall survival in 
this malignancy [7]. 
The patient described in this report received multiple therapeutic agents, including 
some quite ‘old drugs’ (e.g., altretamine) as well as newer hormonal (e.g., anastrozole) 
pharmaceuticals. Despite the striking differences in the number of years these various 
agents have been employed in the management of ovarian cancer, the fundamental goal 
for the delivery of each of these treatments is the same: to extend survival and at the same 
time optimize the quality of life of the individual patient [1].  
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As this case makes clear, management decisions need to be individualized based on 
specific signs (e.g., progressive large volume intra-abdominal disease), symptoms (e.g., 
pelvic pain), and circumstances (e.g., the distance a patient lives from the treatment 
center). Inclusion of the patient and her family in this complex deliberative process is 
essential. Finally, while it is reasonable to conclude that currently this particular case 
history likely represents the unique management challenges associated with a patient 
whose course is at ‘the end of the tail’ of the recurrent ovarian cancer survival curve, it is 
not inappropriate to speculate that extended survival of this magnitude will be far less of a 
novelty in the not-so-distant future [1]. 
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